Clinical Research

Elizabeth Swisher, MD

April 8, 2024

Elizabeth Swisher, MDUniversity of WashingtonSeattle, WA Optimizing genetic testing uptake and outcomes for hereditary ovarian cancer risk As genetic testing for cancer risk becomes increasingly accessible, the goal of eradicating hereditary ovarian cancer through comprehensive genetic testing and effective prevention is tantalizingly close. However, several large studies have revealed that a large minority of people […]

Read More

Viola Heinzelmann-Schwarz, MD

April 2, 2021

Multimodal single-cell surfaceome and transcriptome profiling of longitudinal high-grade ovarian cancer ascites samples Despite advances in the initial treatment of high-grade serous ovarian cancer (HGSOC), recurrence of the disease is very common and effective treatment of recurrent HGSOC remains a major challenge. In order for a tumor to gain resistance to chemotherapy and progress into […]

Read More

Melissa Thrall, MD

August 18, 2019

Melissa Thrall, MDUniversity of Washington A population based evaluation of the use and outcomes of neoadjuvant chemotherapy The current standard of care for the treatment of advanced stage ovarian cancer involves surgery with a maximal effort to remove all visible tumor followed by the administration of platinum based chemotherapy. However not all women with advanced […]

Read More

Barbara Norquist, MD

August 18, 2019

Barbara Norquist, MDUniversity of Washington2013 Skacel Family Scholar Genes Contributing to Hereditary Ovarian Cancer in BRCA1/2 Wildtype Families Nearly a quarter of ovarian cancer cases may be caused by inherited mutations, with a significant portion caused by mutations in genes other than BRCA1 and BRCA2 (BRCA1/2). Next generation sequencing techniques have made it possible to […]

Read More

Elizabeth Poole, PhD

August 18, 2019

Elizabeth Poole, PhDBrigham and Women’s Hospital2015 Skacel Family Scholar Medication use and ovarian cancer survival Although factors that contribute to ovarian cancer risk prior to diagnosis are currently being teased apart, factors which contribute to survival after a diagnosis of ovarian cancer have not yet been well studied. Dr. Poole’s project will develop the Nurses’ […]

Read More

Elizabeth Swisher, MD

August 18, 2019

Elizabeth Swisher, MDUniversity of Washington Falloposcopy: A Novel Approach to Ovarian Cancer Detection and Prevention Recent data suggest that many presumed ovarian or peritoneal carcinomas may actually arise in the fallopian tubes (FT). If true, early detection of ovarian carcinoma should focus on viewing and sampling the FT. A new technology has been developed at […]

Read More

Resham Bhattacharya, PhD

August 18, 2019

Resham Bhattacharya, PhDMayo Clinic Therapeutic targeting of Bmi-1 in ovarian cancer While platinum-based drugs continue to be the foundation of therapy for ovarian cancer, chemoresistance remains the main challenge for effective management of recurrent disease. The development of new therapeutic strategies to combat ovarian cancer is needed. This study will examine the therapeutic potential of […]

Read More

Peter Kuhn, PhD

August 17, 2019

Peter Kuhn, PhDUniversity of Southern California Single-cell molecular profiling of biopsies of epithelial cancer Next-generation sequencing of single cancer cells identified from the blood of ovarian cancer patients can potentially guide treatment decisions, identify recurrence early, and lead to earlier and more accurate diagnosis of the disease. Dr. Kuhn will use a “fluid biopsy” to […]

Read More

André Lieber, MD, PhD

August 16, 2019

André Lieber, MD, PhDUniversity of Washington2016  Lester and Bernice Smith Challenge Award Grant Immuno-Prophylaxis of Ovarian Cancer Associated with High-Risk Germ Line Mutations Dr. Lieber’s project proposes a prophylactic gene therapy approach to introduce genes encoding antibodies into hematopoietic stem cells from the bone marrow. Ovarian cancer cells normally produce signals that inhibit immune cells […]

Read More